Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World check: does zepzelca help advanced lung cancer patients?

NCT ID NCT04894591

Disease control Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 272 adults with extensive-stage small cell lung cancer who were taking the drug Zepzelca. Researchers wanted to see how well the drug worked and how safe it was in real-world settings, not just in controlled trials. The goal was to measure tumor shrinkage, survival time, and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

272 people

The number who actually took part.

Started

Jun 2021

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants with extensive SCLC treated with Zepzelca.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient has initiated or will be receiving Zepzelca treatment in line with the local Zepzelca prescribing information. 2. Decision to initiate treatment with Zepzelca was made as per investigator's routine treatment practice prior to enrollment in the study. 3. Patient, or a legally acceptable representative, signed the informed consent before any study-related activities are undertaken. 4. Patients initiating Zepzelca treatment in second-line. 5. Patients who are sensitive to platinum-based chemotherapy with CTFI≥180 days. The CTFI is defined as the length of time from last platinum dose to time of relapse or disease progression. 6. Eastern Cooperative Oncology Group performance status (ECOG) ≤1 Exclusion Criteria: 1. Patients who discontinued a prior Zepzelca treatment due to adverse events. 2. Patient who received more than 2 cycles of Zepzelca treatment in their current treatment schedule. 3. Patient received treatment with any investigational agent within 30 days prior to first Zepzelca infusion or plans to use another investigational agent while receiving Zepzelca. 4. Known CNS involvement prior to Zepzelca treatment. 5. Patients who were treated with Zepzelca in later lines rather than in second-line treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Extensive-stage small-cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Extensive-stage small-cell lung cancer

Contacts and locations

Locations

  • ASCLEPES Research Centers

    Brooksville, Florida, 34613, United States

  • Baptist Cancer Center

    Memphis, Tennessee, 38120, United States

  • Baptist Health Lexington

    Lexington, Kentucky, 40503, United States

  • Baylor Scott & White Medical Center - Temple

    Temple, Texas, 76508, United States

  • Benefis Medical Group

    Great Falls, Montana, 59405, United States

  • CIUSSS de L'Estrie - CHUS - Hopital Fleurimont

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Cancer Center of Kansas

    Wichita, Kansas, 67214, United States

  • Cape Breton Cancer Centre

    Sydney, Nova Scotia, B1P 1P3, Canada

  • Carolina Blood & Cancer Care Associates

    Rock Hill, South Carolina, 29732, United States

  • Center for Clinical Research-Rochester General Hospital

    Rochester, New York, 14625, United States

  • Central Care Cancer Center

    Bolivar, Missouri, 65613, United States

  • Centre Integre Universitaire de Sante et de Services Sociaux du Saguenay-Lac-Saint-Jean

    Chicoutimi, Quebec, G7H 5H6, Canada

  • Centre integre de Sante Et De Services Sociaux du Bas-Saint-Laurent Hopital regional de Rimousk

    Rimouski, Quebec, G5L 5T1, Canada

  • Centre integre de sante et de services sociaux de Chaudiere-Appalaches

    Lévis, Quebec, G6V 3Z1, Canada

  • Charleston Hematology Oncology Associates, PA

    Charleston, South Carolina, 29414, United States

  • Clearview Cancer Institute

    Huntsville, Alabama, 35805, United States

  • Eastern Connecticut Hematology and Oncology

    Norwich, Connecticut, 06360, United States

  • Gabrail Cancer Center Research

    Canton, Ohio, 44718, United States

  • Goshen Health Center for Cancer Care

    Goshen, Indiana, 46526, United States

  • Lankenau Institute for Medical Research

    Wynnewood, Pennsylvania, 19096, United States

  • Lexington Oncology Associates

    West Columbia, South Carolina, 29169, United States

  • MMCORC - HealthPartners Institute

    Saint Louis Park, Minnesota, 55416, United States

  • Mid-Illinois Hematology & Oncology Associates

    Normal, Illinois, 61761, United States

  • Montefiore Medical Center (MMC) - Montefiore Medical Park (MMP)

    The Bronx, New York, 10461, United States

  • Monument Health Cancer Care Institute

    Rapid City, South Dakota, 57701, United States

  • Pikeville Medical Center - Leonard Lawson Cancer Center

    Pikeville, Kentucky, 41501, United States

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • Regional Cancer Care Associates LLC (RCCA)

    Hackensack, New Jersey, 07601, United States

  • Singing River Health System

    Pascagoula, Mississippi, 39581, United States

  • Siouxland Regional Cancer Center dba June E. Nylen Cancer Center

    Sioux City, Iowa, 51101, United States

  • Southlake Regional Health Centre (York County Hospital)

    Newmarket, Ontario, L3Y 2P9, Canada

  • Stormont-Vail Cancer Center-Stormont-Vail Healthcare - Cotton-O'Neil Cancer Center

    Topeka, Kansas, 66606, United States

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, K1H 8L6, Canada

  • ThedaCare Regional Cancer Center

    Appleton, Wisconsin, 54911, United States

  • Tranquil Clinical Research

    Webster, Texas, 77598, United States

  • Tri-County Hematology & Oncology Associates, Inc

    Massillon, Ohio, 44646, United States

  • Trinity Cancercare Center

    Minot, North Dakota, 58701, United States

  • Universite Laval - Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ) (Hopital Laval)

    Sainte-Foy, Quebec, G1V 4G5, Canada

  • University of North Carolina NASH Cancer Center

    Rocky Mount, North Carolina, 27804, United States

  • West Jefferson Cancer Center

    Marrero, Louisiana, 70072, United States

  • Woodlands Medical Specialists - Woodlands Center For Specialized Medicine

    Pensacola, Florida, 32503, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.